In contrast to systemic chemotherapy, the local administration of chemotherapeutics potentially optimizes their accumulation in the tumor tissues and alleviates the associated systemic toxicity. However, the lack of control over the release of encapsulated drugs and their degradation represents a major challenge for local drug delivery systems. In this study, we developed a series of epirubicin (EPI)-loaded poly(ε-caprolactone)/poly(lactide-co-glycolide) (PCL/PLGA) nanofiber capsules with adjustable rates of drug release and degradation for local malignancy chemotherapy. The core-sheath PCL/PLGA nanofiber capsules containing 15.0 or 25.0 wt% of PCL in the sheath and 0, 5.0, or 10.0 wt% of EPI in the core were produced by emulsion electrospinning technology. The EPI release and degradation of the nanofiber capsules could be accelerated by decreasing the PCL content in the sheath. More importantly, the EPI-loaded PCL/PLGA nanofiber capsules effectively inhibited the growth of tumor cells in vitro and in vivo. Moreover, none of the laden nanofiber capsules caused apparent systemic toxicity. Hence, the cytostatic-loaded electrospun polyester nanofiber capsules displayed controlled drug release and degradation, along with satisfactory antitumor properties, indicating their great potential in local malignancy chemotherapy.

中文翻译：

---

载有纳米纤维的局部恶性化学疗法胶囊。

与全身化学疗法相比，化学疗法的局部给药潜在地优化了它们在肿瘤组织中的积累并减轻了相关的全身毒性。但是，对封装药物的释放及其降解缺乏控制，这是局部药物递送系统的主要挑战。在这项研究中，我们开发了一系列装载表柔比星（EPI）的聚（ε-己内酯）/聚（丙交酯）共聚物-乙交酯（PCL / PLGA）纳米纤维胶囊，具有可调节的药物释放和降解速率，用于局部恶性化疗。通过乳液静电纺丝技术生产了芯鞘PCL / PLGA纳米纤维胶囊，其在鞘中包含15.0或25.0 wt％的PCL，在芯中包含0、5.0或10.0 wt％的EPI。纳米纤维胶囊的EPI释放和降解可以通过减少鞘中PCL的含量来加速。更重要的是，EPI负载的PCL / PLGA纳米纤维胶囊在体外和体内均能有效抑制肿瘤细胞的生长。此外，没有一个载有纳米纤维的胶囊引起明显的全身毒性。因此，载有细胞抑制剂的静电纺丝聚酯纳米纤维胶囊显示出受控的药物释放和降解以及令人满意的抗肿瘤特性，表明它们在局部恶性化学疗法中具有巨大潜力。